Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Jiegeng Decoction in Improving Allergic Asthma
ACS Omega · 19.12.2023 · 8 (50) · 48081-48090
DOI: 10.1021/acsomega.3c06914 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 06.12.2023. Verfasst von Zhihai Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science, Technology and Innovation Commission of Shenzhen Municipality, Nebulized Inhalation Herbal Product Development.
Abstract (Originalsprache)
Allergic asthma is a prevalent form of asthma that is characterized primarily by airway inflammation. Jiegeng decoction (JGT) is a traditional Chinese herbal formula known for its anti-inflammatory properties and has been used to treat respiratory diseases for centuries. This study aimed to investigate the biological effects and mechanisms of action of JGT in improving allergic asthma. An experimental allergic asthma mouse model was established using ovalbumin. The results showed that JGT significantly improved inflammation cell infiltration in the lung tissue of allergic asthmatic mice and the inflammatory environment of Th2 cells in the bronchoalveolar lavage fluid while also reducing serum IgE levels. Subsequently, 38 components of JGT were identified through liquid chromatography-mass spectrometry. Network pharmacology revealed that regulating inflammation and immune responses is the primary biological process by which JGT improves allergic asthma, with Th2 cell differentiation and the JAK-STAT signaling pathway being the key mechanisms of action. Finally, qPCR, flow cytometry, and Western blotting were used to validate that JGT inhibited Th2 cell differentiation by blocking the JAK1-STAT6 signaling pathway in CD4+ T cells, ultimately improving allergic asthma. This study provides a novel perspective on the therapeutic potential of JGT in the treatment of allergic asthma.
Autor:innen und Institutionen
- School of Life Sciences, Beijing University of Chinese Medicine, Beijing 100029, China.
- National Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs, Beijing 100700, China.
- State Key Laboratory of Dao-di Herbs, National Resource Center for Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
- Shenzhen Research Institute, Beijing University of Chinese Medicine, Shenzhen 518118, China.
ORCID-Profile: Zhihai Wu, Yuanyuan Shi
Förderung
- Science, Technology and Innovation Commission of Shenzhen Municipality
- Nebulized Inhalation Herbal Product Development
Zitieren
APA
Wu, Z., Luo, Z., Sun, W., Shi, Y., & Ding, Q. (2023). Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Jiegeng Decoction in Improving Allergic Asthma. ACS Omega, 8(50), 48081-48090. https://doi.org/10.1021/acsomega.3c06914
Vancouver
Wu Z, Luo Z, Sun W, Shi Y, Ding Q. Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Jiegeng Decoction in Improving Allergic Asthma. ACS Omega. 2023;8(50):48081-48090. doi:10.1021/acsomega.3c06914
BibTeX
@article{Wu2023,
author = {Wu, Zhihai and Luo, Zhiqiang and Sun, Wen and Shi, Yuanyuan and Ding, Qi},
title = {Integrating Network Pharmacology and Experimental Validation to Elucidate the Mechanism of Jiegeng Decoction in Improving Allergic Asthma},
journal = {ACS Omega},
year = {2023},
volume = {8},
number = {50},
pages = {48081--48090},
doi = {10.1021/acsomega.3c06914}
}
EUVIMED